Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 12Carcinoma, Hepatocellular 8Small Cell Lung Carcinoma 7Cholangiocarcinoma 7Neoplasms 6Carcinoma 6Urinary Bladder Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Biliary Tract Neoplasms 4Triple Negative Breast Neoplasms 3Neoplasms by Site 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 3Pathologic Complete Response 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Neoplasms by Histologic Type 2Liver Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Bile Duct Neoplasms 2Adenocarcinoma 2Vaccinia 1Unresectable Hepatocellular Carcinoma 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Carboplatin 5Radiotherapy 4Radiation 3Radiotherapy, Conformal 2Platinum 2Pemetrexed 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Disulfides 2Cisplatin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1methoxyamine 1lazertinib 1durvalumab 1capmatinib 1Taxes 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Nivolumab 1Metformin 1Ipilimumab 1Granulocyte Colony-Stimulating Factor 1Gefitinib 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × durvalumab × 30 days × Clear all
NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡